Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (15866)	6/24/2002 12:51:37 AM
From: aknahow	Respond to of 17367

Robert, Sepsis is the next indication, IMO. BAX is now using the word linked to "BPI Neuprex". Used right after mention of Crohn's. Try the BAX June 20 conference call. If this comes to pass 100% of all cost for a large important indication will be paid by BAX plus Xoma may manufacture but may not to avoid switching production during trials. Crohn's trial must be on track and not a failure as I thought or one year into phase II it would not have been mentioned. http://:www.baxter.com See upper right, using external player, comment found at about 42 min.